advanced stage colorectal cancer that recieves FOLFIRI chemotherapy regimen activated charcoal , quality of life , colorectal cancer,chemotherapy induced diarrhea ,irinotecan ,
Conditions
Interventions
patients with advanced colorectal cancer who are receiving the FOLFIRI chemotherapy regimen. These patients will be randomly assigned to receive activated charcoal as a prophylactic treatment.,patient
Experimental Drug,Placebo Comparator Drug
activated charcoal arm ,placebo arm
Sponsors
Rajavithi hospital, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1 advanced colorectal cancer 2 receive FOLFIRI chemotherapy with irinotecan 160 mg/m2 every 2 week 3 age >= 18 years 4 ECOG score 0-1
Exclusion criteria
Exclusion criteria: 1 patients with baseline diarrhea > 4 times /day 2 patients with ileostomy 3 patient receive anti EGFR therapy 4 patient with pregnancy or breastfeeding 5allergic to activated charcoal 6 patients who are at risk for bowel obstruction 7 patients with baseline constipation 8 patients with baseline vomiting 9 patients with baseline abdominal pain
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| diarrhea above grade 2 definition increase of stool more than 7 times per day over baseline or hospitalization indicated 2 weeks manual diarhea count : | — |
Secondary
| Measure | Time frame |
|---|---|
| diarrhea all grades definition collective occurrence of diarrhea at different severity level 2 weeks manual diarrhea count | — |
Countries
Thailand
Contacts
Public ContactNattagorn Taweepoca
rajavithi hospital
Outcome results
None listed